• GlucoTrack’s subsidiary Lōkahi Therapeutics secured its first external engagement for its proprietary ai² PIPELINE asset-identification platform.
• Innovate GBM engaged two ai² PIPELINE teams to identify brain tumor therapeutic assets for potential licensing and development.
• Work will focus on glioblastoma and other brain tumors; Innovate GBM will decide independently whether to pursue any identified assets.
• Move positions ai² PIPELINE as a revenue-generating platform, extending beyond internal discovery across Lōkahi’s 14 university collaborations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260923982243) on September 23, 2026, and is solely responsible for the information contained therein.